What Letoval Treats: Main Uses and Benefits

Letoval is used across therapeutic domains involving conditions fueled by estrogen, with its main benefits spanning both oncology and reproductive medicine. The drug is relevant in the management of hormone-driven malignancies and is also commonly utilized in specialized fertility protocols.

This medication's support is generally provided across several critical conditions, including managing the risk of hormone receptor-positive breast cancer returning, controlling advanced or metastatic disease, and addressing anovulatory infertility such as that often seen with Polycystic Ovary Syndrome (PCOS). This support assists with easing the overall symptom load associated with widespread manifestations and managing the risk of relapse after initial therapy.

Quick Fact: Relief for Estrogen-Driven Conditions

Letoval eligibility is strictly defined by regulatory documents, allowing its standard use primarily for postmenopausal women. The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to the active substance. Furthermore, due to the potential for fetal harm, Letoval is contraindicated during pregnancy, while breastfeeding, and in women of premenopausal endocrine status (including perimenopausal women). Confirmation of postmenopausal status is a prerequisite for starting therapy.

Use in the pediatric population (children and adolescents) is not recommended because its safety and effectiveness have not been established. Standard use is permitted for adult and elderly patients without dose adjustment.

Eligibility is also conditional on organ function and comorbidities. Patients with severe hepatic impairment (Child-Pugh C) require close supervision. Use in patients with severe renal insufficiency (creatinine clearance less than 10 mL/min) is noted as having insufficient data and requires careful consideration. Finally, individuals at increased risk of osteoporosis or with hypercholesterolemia are required to undergo formal monitoring protocols as specified in the official labeling.

Interaction Scope

Interaction Classifications (High-Level)

Resulting Interaction Structure

Regulatory documents establish that the interaction profile is defined by two key constraints: hormonal antagonism and metabolic liability. Avoidance of co-administration is specified for Tamoxifen and other anti-oestrogens, which are documented to substantially decrease Letoval's plasma concentrations and diminish its action. Caution is formally indicated for concomitant use with narrow therapeutic index medicines (e.g., Phenytoin) that are cleared by CYP2A6 or CYP2C19, reflecting Letoval’s inhibitory properties. Conversely, strong CYP inducers may decrease Letoval's serum concentration. The product can be administered with or without food, and there are no specific timing-separation rules. The profile notes a population constraint where reduced clearance in severe hepatic impairment doubles exposure.

Letoval's core function is executed by its active component, Letrozole, which acts as a non-steroidal inhibitor that binds competitively and reversibly to the heme of the aromatase enzyme (CYP19). This molecular interaction physically blocks the enzyme's active site, preventing it from converting androgen precursors into estrogens. This mechanism operates upstream of the receptor, addressing the synthesis of the hormone, and is highly selective for aromatase, ensuring minimal interference with other steroidogenic pathways. The enzymatic blockade leads to a significant reduction (typically 98%) in the body's circulating levels of estrogens (estradiol and estrone). This systemic change establishes a state of estrogen scarcity, which alters the activity of hormone-sensitive biological processes across multiple tissues, including peripheral sites like fat and muscle. The resulting alteration of the systemic endocrine environment—the maintenance of this low-estrogen condition—is the central physiological adjustment produced by the drug, directly influencing all biological processes that rely on estrogen signaling.

Official Administration Guidelines for Letoval

Letoval, containing Letrozole, is administered through the oral route as a 2.5 mg film-coated tablet. A standardized dosing protocol is utilized that varies by clinical setting and the patient's liver function, but not by age or renal impairment status (for creatinine clearance ge 10 mL/min).

Dosing Schedule and Timing

The recommended dose across all main approved uses is one 2.5 mg tablet taken once daily. The tablet can be taken with or without food, simplifying the daily administration schedule, and should be swallowed whole. Patients should aim to take the medicine at approximately the same time each day.

Treatment duration is not fixed across all uses. In the adjuvant setting, treatment typically continues for a total of five years or until disease relapse. For advanced disease, administration is continued until the tumor progression is evident.

Procedural Use and Adjustments

If a dose is missed, the dose is taken as soon as remembered. However, if it is almost time for the next scheduled dose (e.g., within 2 to 3 hours), the missed dose must be skipped to prevent over-exposure, and the regular schedule should be resumed. Doses must not be doubled.

Administration frequency must be modified for specific populations. For patients with severe hepatic impairment (Child-Pugh C), the dose is reduced by 50% and administered as 2.5 mg every other day due to anticipated increases in systemic exposure. No such adjustment is mandated for elderly patients or those with mild-to-moderate liver impairment.

Research Evidence / Overview of Studies for Letoval

Evidence for Letoval in Early-Stage Breast Cancer (Post-Menopause)

Research has examined the use of Letoval in post-menopausal women who have already completed their initial treatment for hormone-sensitive, early-stage breast cancer, such as surgery and radiation, to explore the time until cancer recurrence. Studies generally suggest that taking Letoval for an additional period was associated with patterns related to the time until cancer recurrence or the development of cancer in the opposite breast, compared to a comparison group. However, the effects on overall survival are not fully established or have been mixed, and more research is ongoing to clarify the long-term picture.

Evidence for Letoval in Advanced Breast Cancer (Post-Menopause)

Letoval was studied for women with hormone-sensitive breast cancer that has spread locally or to distant sites in the body. These trials monitored outcomes related to the time until the cancer progressed in this setting. Research was associated with patterns related to the time until disease progression, particularly when combined with other targeted therapies. The data show patterns related to tumor response in specific observed groups, but research provides context but not individual predictions about how quickly the cancer can progress for any single person.

Long-term Studies and Follow-up Research

Long-term follow-up was evaluated in studies of Letoval to understand the patterns observed over time. Because some participants in the original trials chose to switch treatments later, long-term effects are not fully established in all cases. The follow-up durations were limited in some studies, meaning we have limited information for long-term outcomes regarding the absolute time of death. The research contributes to understanding patterns over time, but certainty remains low for some of the very late effects.

What is Still Uncertain About Letoval Research

Key uncertainties and research gaps remain. The overall impact of Letoval on the absolute time a person lives (overall survival) in the early-stage setting is not fully established or findings were mixed. Comparative evidence is lacking for many direct comparisons with all other possible hormone-based treatments. Furthermore, subgroup findings are uncertain—meaning it is not always clear which specific individuals are most likely to experience a prolonged time before cancer progression versus those for whom the pattern of benefit may be less clear.

Key Studies & References

1. Extended Letrozole Therapy After Five Years of an Aromatase Inhibitor in Postmenopausal Women with Early-Stage Breast Cancer (MA.17R Trial)
2. Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole in postmenopausal women with hormone-receptor+ breast cancer
3. Adjuvant letrozole versus tamoxifen in postmenopausal women with early breast cancer: an updated analysis of the BIG 1-98 trial
4. Letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: A randomized double-blind trial

Common questions about Letoval (FAQ)

Q: What is the main purpose of Letoval for most people?

Letoval (Letrozole) is officially indicated for the treatment of breast cancer in postmenopausal women. This includes the initial treatment of advanced disease, as well as use after other treatments have been completed (known as adjuvant and extended adjuvant therapy). Regulatory documents describe the medication as being indicated for hormone receptor-positive breast cancer.

Q: Is Letoval considered a treatment for all types of breast cancer?

No. Official regulatory information indicates that Letoval is specifically approved for treating hormone receptor-positive breast cancer. The official indication does not include use for hormone receptor-negative breast cancer, which constitutes a contraindication.

Q: Is Letoval safe to take if I have liver problems?

The official product information addresses use in patients with liver impairment. For mild to moderate hepatic impairment, regulatory documents state no dosage adjustment is formally required. However, in the case of severe hepatic impairment (Child-Pugh C), an adjustment to the dose is specified in the prescribing information due to anticipated increases in systemic exposure.

Q: Are there any known long-term effects associated with using Letoval?

Regulatory documents and long-term studies highlight two primary risks associated with its use. These include decreases in bone mineral density (BMD) and an associated increase in the risk of fracture, as documented in official warnings. Additionally, an increase in total cholesterol (hypercholesterolemia) is noted. Monitoring protocols for these conditions are generally recommended by official labeling.

Q: What does the term 'contraindication' mean regarding Letoval?

A contraindication refers to a specific condition or factor where the use of the medication is strictly prohibited by regulatory standards. For Letoval, official warnings state the medication must not be used in women who are pregnant or in women who have a known hypersensitivity (severe allergic reaction) to the active ingredient.

Q: How do I know if the side effects I am experiencing are serious?

Serious adverse reactions that require immediate medical attention may involve signs of a blood clot, such as sudden pain, swelling, or redness in a limb. Other signs noted in patient safety information include symptoms related to stroke or heart attack, such as sudden chest pain or face drooping. Official patient safety information states that if symptoms of a serious adverse event are observed, the patient should seek immediate medical attention.

Q: Can I take other prescription medications while using Letoval?

Regulatory labeling specifies that patients are required to inform their healthcare professional about all medicines being taken. Letoval may interact with products metabolized by specific liver enzymes (CYP2A6/CYP2C19). It is particularly cautioned not to be taken concurrently with any therapies containing estrogen.

Q: Are there any specific laboratory tests required while taking Letoval?

Due to the potential effects on the body, official warnings recommend monitoring specific lab values. Monitoring of bone mineral density (BMD) is recommended in official guidelines. Likewise, monitoring of serum cholesterol levels is advised because total cholesterol may increase during treatment.

Q: What is the evidence theme regarding Letoval's effectiveness in different patient groups?

The core clinical trials used for approval primarily focused on postmenopausal women with hormone receptor-positive breast cancer. Regulatory documents note that while effectiveness has been examined in this group, the impact on metrics like overall survival in the early-stage setting and the specific results within patient subgroups remain under continued study and are not definitively clear.

Q: What is the typical timeframe for maximum effect with Letoval?

The rapid and profound suppression of estrogen synthesis is typically observed within 2 to 3 days of treatment initiation. The drug's concentration in the blood, known as steady-state, is generally reached approximately 2 to 6 weeks after continuous daily dosing.

Q: What are the regulatory classifications of Letoval?

Letoval (Letrozole) is classified as a prescription-only (Rx) medication by regulatory bodies. According to official records, the drug is not classified as a controlled substance (Not a CSA Schedule drug) in the United States.

Q: Can Letoval affect my ability to drive or operate machinery?

Official warnings state that fatigue, dizziness, and somnolence (drowsiness) have been reported as side effects with this medication. Official warnings recommend caution during activities like driving or operating machinery because these effects may occur.

Q: How is Letoval eliminated from the body?

The body primarily eliminates Letoval through a process called hepatic metabolism, which means it is processed by the liver using specific enzymes. The medication is then mostly excreted in the urine in the form of an inactive metabolite, meaning the drug has been broken down and is no longer active.

Q: Is there a generic version of Letoval available?

Yes. Official drug status listings confirm that generic versions of the active ingredient, Letrozole (2.5 mg tablets), have been approved. These approvals are based on the standard regulatory requirements for generic medications.

Q: What is the purpose of the black box warning (if applicable) mentioned for Letoval?

Official regulatory prescribing information confirms that Letoval does not have a Boxed Warning (often referred to as a black box warning) in its FDA labeling. A boxed warning is reserved for drug products that carry the most serious risks.

Q: How long does Letoval stay in my system?

The amount of time it takes for the drug concentration in the body to decrease by half, known as the terminal elimination half-life, is approximately 2 days (41 to 48 hours). Due to this time frame, the medication maintains a relatively stable level in the body once a steady state is reached.

Q: Can Letoval interact with herbal supplements like St. John's Wort?

Official patient information advises that certain herbal remedies or supplements, particularly those used for menopausal symptoms, may interfere with the effectiveness of the medication. This type of combination is generally cautioned against due to potential interactions.

Storage Requirements

Letoval must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted between 15 C and 30 C. The tablets must be kept in the original, tightly closed container and protected from excess heat and moisture; storage in areas like the bathroom is strictly prohibited. For safety, the medication must always be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Letoval should be disposed of using a drug take-back program or an authorized collection site. If a take-back option is unavailable, the tablets should be removed from their container, mixed with an unappealing substance (e.g., used coffee grounds), sealed in a bag, and then placed in the household trash. Do not discard Letoval by flushing it down a toilet or pouring it down a drain.